Analytical Data
-
Gene name
GTF2A1
- Application
-
Alternative Names
GTF2-A1; TF2A1; TFIIA; Transcription Initiation Factor IIA Subunit 1; Transcription initiation factor TFIIA 42 kDa subunit
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P52655
-
Expression Region
Ala2~Asp274
-
Molecular Weight
60kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GTF2A1, or General Transcription Factor II A Subunit 1, is a crucial protein that plays a significant role in the formation of the pre-initiation complex, facilitating the transcription of protein-coding genes by RNA polymerase II. It is involved in the essential process of gene expression regulation, impacting various cellular functions and developmental processes. Dysregulation or mutations in GTF2A1 have been associated with several diseases, including certain types of cancer and developmental disorders. Researchers have increasingly focused on GTF2A1 as a potential biomarker and therapeutic target due to its pivotal role in transcriptional control. The study of recombinant GTF2A1 not only aids in understanding its functional mechanisms but also paves the way for the development of novel strategies to manipulate gene expression for therapeutic purposes. By producing and characterizing recombinant GTF2A1, scientists aim to elucidate its structure-function relationships, interactions with other transcription factors, and potential implications in disease states, ultimately contributing to the advancement of targeted treatments and interventions in transcription-related disorders.
